Reata

Quote






It’s the right call.

Get rid of the old crew that ruined the company and bring in some fresh products and drugs.

It wasn’t just the former execs. Everything about Biogen needs a refresh.
 












anonymous said:
Viehbacher likely overpaid but it doesn’t look like a bad asset.
Click to expand...

Time will tell, but it appears a bit overpriced. Not a bad fit though. If CV wants to accelerate Skyclaris, it shouldn’t be too hard. Reata wasn’t even trying since they were looking for a fast buyout. May want to start by giving health systems access instead of forcing docs to use a random SP.
 






I don’t get the valuation. Analysts estimate Skyclarys revenue at 400M by 2030 with the patent cliff in 2033 I believe. Bardoxolone is toast and there’s nothing else of note in the pipeline.
 






Viehbacher isn’t that good at BD. The VERY profitable Regeneron deal at Sanofi was done before he landed there. The Genzyme purchase was his and was arguably a pretty good trade. Everything else that happened on his watch was totally forgettable though.
 












anonymous said:
I don’t get the valuation. Analysts estimate Skyclarys revenue at 400M by 2030 with the patent cliff in 2033 I believe. Bardoxolone is toast and there’s nothing else of note in the pipeline.
Click to expand...

Reata did absolutely no pre market prep and has hardly tried to get this product moving through institutions where these patients are seen. They brought in a bunch of folks, gave them title bumps and waited for a buyer. Unless BIIB raises the price, I don’t see the payoff long term.

the Genzyme deal at Sanofi led to waves of cuts to make it work (and handing them a Sanofi MS asset to look like they had something to launch).

Good luck
 






anonymous said:
Reata did absolutely no pre market prep and has hardly tried to get this product moving through institutions where these patients are seen. They brought in a bunch of folks, gave them title bumps and waited for a buyer. Unless BIIB raises the price, I don’t see the payoff long term.

the Genzyme deal at Sanofi led to waves of cuts to make it work (and handing them a Sanofi MS asset to look like they had something to launch).

Good luck
Click to expand...

Price gouging is Biogen’s trademarks. Look at what they tried to do with Adu. Their reputation couldn’t be lower these days.
 


















Top Bottom
Back
Quote